Key result
Intensified antiplatelet therapies, such as double-dose clopidogrel, reduced 30-day MACE compared to standard therapy (3.9% vs 4.5%; HR 0.86; p=0.039) in patients undergoing PCI.
Why the study?
The optimal antiplatelet strategy after PCI remains debated, particularly in patients with ACS, high on-treatment platelet reactivity, or CYP2C19 loss-of-function alleles.
Does intensified or alternative antiplatelet therapy reduce MACE without significantly increasing major bleeding in post-PCI patients?
Systematic Review (n=52,000)
Yes
Does intensified or alternative antiplatelet therapy reduce MACE without significantly increasing major bleeding in post-PCI patients?
Intensified antiplatelet regimens, including double-dose clopidogrel, ticagrelor, and prasugrel, modestly improve early ischemic outcomes after PCI, highlighting the potential for individualized, genotype- and reactivity-guided strategies.
Background The optimal antiplatelet strategy after percutaneous coronary intervention (PCI) remains debated, particularly in patients with acute coronary syndrome (ACS), high on-treatment platelet reactivity (HTPR), or CYP2C19 loss-of-function alleles. Intensified regimens, including double-dose clopidogrel (DDAT), cilostazol-based triple therapy (TAT), ticagrelor, and prasugrel, have been evaluated to improve outcomes without increasing bleeding risk. Objectives To consolidate evidence comparing intensified or alternative antiplatelet therapies after PCI, focusing on efficacy (major adverse cardiovascular events [MACE]) and safety (major bleeding). Methods Data were synthesized from seven randomized controlled trials and one meta-analysis including approximately 52,000 PCI patients. Key studies comprised HOST-ASSURE, TADCLOT, TRIGGER-PCI, CURRENT-OASIS 7, and a CYP2C19-guided meta-analysis. Primary endpoints included MACE (death, myocardial infarction, stent thrombosis, stroke, or revascularization) and major bleeding (PLATO or BARC criteria). Results In CURRENT-OASIS 7 (n=17,263 PCI subset), double-dose clopidogrel reduced 30-day MACE (3.9% vs 4.5%; HR 0.86; p=0.039) and stent thrombosis (0.7% vs 1.3%; p=0.0001) but increased major bleeding (1.6% vs 1.1%; p=0.009). Cilostazol-based TAT was noninferior to DDAT (1.2% vs 1.4%) and lowered high platelet reactivity (3.3% vs 26.7%; p=0.012). Ticagrelor showed no superiority over twice-daily clopidogrel at 30 days (MACE 2.2% vs 2.9%; HR 0.75; p=0.28) but reduced early MACE within 14 days (HR 0.46; p=0.02). Prasugrel achieved stronger platelet inhibition (PRU 245→80; p<0.001) and reduced HTPR (20.4% vs 42%; p=0.02) versus clopidogrel. The CYP2C19 meta-analysis demonstrated ticagrelor reduced MACE by 68% (OR 0.32; p<0.00001) without increasing major bleeding. Conclusions Across >50,000 PCI patients, intensified antiplatelet therapy modestly improved ischemic protection without significantly raising bleeding risk. Ticagrelor and prasugrel offer superior platelet inhibition, while double-dose clopidogrel remains an effective, economical alternative. Cilostazol-based triple therapy is a noninferior option in Asian populations. Individualized, genotype- and reactivity-guided strategies may optimize post-PCI outcomes.
No takes yet. Share an insight, caveat, or question.
A Akhtar (2026) conducted a systematic review in Percutaneous coronary intervention (PCI) (n=52,000). Intensified antiplatelet therapies (double-dose clopidogrel, cilostazol-based triple therapy, ticagrelor, prasugrel) vs. Standard antiplatelet therapy was evaluated on 30-day MACE (death, myocardial infarction, stent thrombosis, stroke, or revascularization) (HR 0.86, p=0.039). Intensified antiplatelet therapies, such as double-dose clopidogrel, reduced 30-day MACE compared to standard therapy (3.9% vs 4.5%; HR 0.86; p=0.039) in patients undergoing PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: